Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2012, Article ID 129605, 14 pages
http://dx.doi.org/10.1155/2012/129605
Research Article

An NR2B-Dependent Decrease in the Expression of trkB Receptors Precedes the Disappearance of Dopaminergic Cells in Substantia Nigra in a Rat Model of Presymptomatic Parkinson's Disease

1Departamento de Biología Celular y Molecular, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Alameda 340, 8331150 Santiago, Chile
2Programa de Biomedicina, Universidad San Sebastián, Zañartu 1482, Ñuñoa, 7780272 Santiago, Chile

Received 10 January 2012; Revised 19 March 2012; Accepted 2 April 2012

Academic Editor: Kah-Leong Lim

Copyright © 2012 Eduardo Riquelme et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Bernheimer, W. Birkmayer, and O. Hornykiewicz, “Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations,” Journal of the Neurological Sciences, vol. 20, no. 4, pp. 415–455, 1973. View at Publisher · View at Google Scholar · View at Scopus
  2. E. Bezard, S. Dovero, C. Prunier et al., “Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease,” Journal of Neuroscience, vol. 21, no. 17, pp. 6853–6861, 2001. View at Google Scholar · View at Scopus
  3. D. Kirik, C. Rosenblad, and A. Björklund, “Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat,” Experimental Neurology, vol. 152, no. 2, pp. 259–277, 1998. View at Publisher · View at Google Scholar · View at Scopus
  4. P. K. Morrish, G. V. Sawle, and D. J. Brooks, “Clinical and [(18F)]dopa PET findings in early Parkinson's disease,” Journal of Neurology Neurosurgery and Psychiatry, vol. 59, no. 6, pp. 597–600, 1995. View at Google Scholar · View at Scopus
  5. A. L. Acheson, M. J. Zigmond, and E. M. Stricker, “Compensatory increase in tyrosine hydroxylase activity in rat brain after intraventricular injections of 6-hydroxydopamine,” Science, vol. 207, no. 4430, pp. 537–540, 1980. View at Google Scholar · View at Scopus
  6. Y. Agid, F. Javoy, and J. Glowinski, “Hyperactivity of remaining dopaminergic neurones after partial destruction of the nigro striatal dopaminergic system in the rat,” Nature New Biology, vol. 245, no. 144, pp. 150–151, 1973. View at Google Scholar · View at Scopus
  7. C. A. Altar and M. R. Marien, “Preservation of dopamine release in the denervated striatum,” Neuroscience Letters, vol. 96, no. 3, pp. 329–334, 1989. View at Google Scholar · View at Scopus
  8. F. Hefti, A. Enz, and E. Melamed, “Partial lesions of the nigrostriatal pathway in the rat. Acceleration of transmitter synthesis and release of surviving dopaminergic neurones by drugs,” Neuropharmacology, vol. 24, no. 1, pp. 19–23, 1985. View at Publisher · View at Google Scholar · View at Scopus
  9. M. J. Zigmond, A. L. Acheson, M. K. Stachowiak, and E. M. Strickerm, “Neurochemical compensation after nigrostriatal bundle injury in an animal model of preclinical Parkinsonism,” Archives of Neurology, vol. 41, no. 8, pp. 856–861, 1984. View at Google Scholar · View at Scopus
  10. M. J. Zigmond, E. D. Abercrombie, T. W. Berger, A. A. Grace, and E. M. Stricker, “Compensations after lesions of central dopaminergic neurons: some clinical and basic implications,” Trends in Neurosciences, vol. 13, no. 7, pp. 290–296, 1990. View at Google Scholar · View at Scopus
  11. G. Bustos, J. Abarca, J. Campusano, V. Bustos, V. Noriega, and E. Aliaga, “Functional interactions between somatodendritic dopamine release, glutamate receptors and brain-derived neurotrophic factor expression in mesencephalic structures of the brain,” Brain Research Reviews, vol. 47, no. 1-3, pp. 126–144, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. E. Aliaga, C. Cárcamo, J. Abarca, L. Tapia-Arancibia, and G. Bustos, “Transient increase of brain derived neurotrophic factor mRNA expression in substantia nigra reticulata after partial lesion of the nigrostriatal dopaminergic pathway,” Molecular Brain Research, vol. 79, no. 1-2, pp. 150–155, 2000. View at Publisher · View at Google Scholar · View at Scopus
  13. G. Bustos, J. Abarca, V. Bustos et al., “NMDA receptors mediate an early up-regulation of brain-derived neurotrophic factor expression in substantia nigra in a rat model of presymptomatic Parkinson's disease,” Journal of Neuroscience Research, vol. 87, no. 10, pp. 2308–2318, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. C. A. Altar, C. B. Boylan, M. Fritsche et al., “Efficacy of brain-derived neurotrophic factor and neurotrophin-3 on neurochemical and behavioral deficits associated with partial nigrostriatal dopamine lesions,” Journal of Neurochemistry, vol. 63, no. 3, pp. 1021–1032, 1994. View at Google Scholar · View at Scopus
  15. C. Hyman, M. Hofer, Y. A. Barde et al., “BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra,” Nature, vol. 350, no. 6315, pp. 230–232, 1991. View at Publisher · View at Google Scholar · View at Scopus
  16. T. Tsukahara, M. Takeda, S. Shimohama et al., “Effects of brain-derived neurotrophic factor on 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced parkinsonism in monkeys,” Neurosurgery, vol. 37, no. 4, pp. 733–741, 1995. View at Google Scholar · View at Scopus
  17. O. Von Bohlen Und Halbach, L. Minichiello, and K. Unsicker, “Haploin-sufficiency for trkB and trkC receptors induces cell loss and accumulation of α-synuclein in the substantia nigra,” FASEB Journal, vol. 19, no. 12, pp. 1740–1742, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Levivier, S. Przedborski, C. Bencsics, and U. J. Kang, “Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease,” Journal of Neuroscience, vol. 15, no. 12, pp. 7810–7820, 1995. View at Google Scholar · View at Scopus
  19. M. J. Porritt, P. E. Batchelor, and D. W. Howells, “Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons,” Experimental Neurology, vol. 192, no. 1, pp. 226–234, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Baydyuk, M. T. Nguyen, and B. Xu, “Chronic deprivation of TrkB signaling leads to selective late-onset nigrostriatal dopaminergic degeneration,” Experimental Neurology, vol. 228, no. 1, pp. 118–125, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. A. M. Canudas, S. Pezzi, J. M. Canals, M. Pallàs, and J. Alberch, “Endogenous brain-derived neurotrophic factor protects dopaminergic nigral neurons against transneuronal degeneration induced by striatal excitotoxic injury,” Molecular Brain Research, vol. 134, no. 1, pp. 147–154, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Barbacid, “The Trk family of neurotrophin receptors,” Journal of Neurobiology, vol. 25, no. 11, pp. 1386–1403, 1994. View at Publisher · View at Google Scholar · View at Scopus
  23. G. Dechant, “Molecular interactions between neurotrophin receptors,” Cell and Tissue Research, vol. 305, no. 2, pp. 229–238, 2001. View at Publisher · View at Google Scholar · View at Scopus
  24. B. Lu, P. T. Pang, and N. H. Woo, “The yin and yang of neurotrophin action,” Nature Reviews Neuroscience, vol. 6, no. 8, pp. 603–614, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. D. W. Howells, M. J. Porritt, J. Y. F. Wong et al., “Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra,” Experimental Neurology, vol. 166, no. 1, pp. 127–135, 2000. View at Publisher · View at Google Scholar · View at Scopus
  26. T. Nishio, S. Furukawa, I. Akiguchi, and N. Sunohara, “Medial nigral dopamine neurons have rich neurotrophin support in humans,” NeuroReport, vol. 9, no. 12, pp. 2847–2851, 1998. View at Google Scholar · View at Scopus
  27. S. Numan and K. Seroogy, “Expression of trkB and trkC mRNAs by adult midbrain dopamine neurons: a double-label in situ hybridization study,” The Journal of Comparative Neurology, vol. 403, pp. 295–308, 1999. View at Google Scholar
  28. K. B. Seroogy, K. H. Lundgren, T. M. D. Tran, K. M. Guthrie, P. J. Isackson, and C. M. Gall, “Dopaminergic neurons in rat ventral midbrain express brain-derived neurotrophic factor and neurotrophin-3 mRNAs,” Journal of Comparative Neurology, vol. 342, no. 3, pp. 321–334, 1994. View at Google Scholar · View at Scopus
  29. E. Riquelme, J. Abarca, and G. Bustos, “Ifenprodil, antagonist of NMDA-NR2B type glutamate receptors, blocks both the decrease in trkB expression and the disappearance of dopaminergic cells in SNc in a rat model of presymptomatic Parkinson's disease,” in Proceedings of the 18th Meeting of the Latinoamerican Society of Pharmacology, vol. 1, p. 123, Coquimbo, Chile, 2008.
  30. G. Paxinos and C. Watson, The Rat Brain in Stereotaxic Coordinates, Acadenic Press, New York, NY, USA, 1986.
  31. M. E. Andres, K. Gysling, S. Aravena, A. Venegas, and G. Bustos, “NMDA-NR1 receptor subunit mRNA expression in rat brain after 6-OH-dopamine induced lesions: a non-isotopic in situ hybridization study,” Journal of Neuroscience Research, vol. 46, pp. 375–384, 1996. View at Google Scholar
  32. C. Marin, M. C. Rodriguez-Oroz, and J. A. Obeso, “Motor complications in Parkinson's disease and the clinical significance of rotational behavior in the rat: have we wasted our time?” Experimental Neurology, vol. 197, no. 2, pp. 269–274, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. W. Dauer and S. Przedborski, “Parkinson's disease: mechanisms and models,” Neuron, vol. 39, no. 6, pp. 889–909, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. H. Sauer and W. H. Oertel, “Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat,” Neuroscience, vol. 59, no. 2, pp. 401–415, 1994. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Shimohama, H. Sawada, Y. Kitamura, and T. Taniguchi, “Disease model: Parkinson's disease,” Trends in Molecular Medicine, vol. 9, no. 8, pp. 360–365, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. Q. Yan, M. Radeke, C. Matheson, J. Talvenheimo, A. Welcher, and S. Feinstein, “Immunocytochemical localization of trkB in the central nervous system of the adult rat,” The Journal of Comparative Neurology, vol. 378, pp. 135–157, 1997. View at Google Scholar
  37. X. F. Zhou, L. F. Parada, D. Soppet, and R. A. Rush, “Distribution of trkB tyrosine kinase immunoreactivity in the rat central nervous system,” Brain Research, vol. 622, no. 1-2, pp. 63–70, 1993. View at Google Scholar · View at Scopus
  38. M. Arundine and M. Tymianski, “Molecular mechanisms of calcium-dependent neurodegeneration in excitotoxicity,” Cell Calcium, vol. 34, no. 4-5, pp. 325–337, 2003. View at Publisher · View at Google Scholar · View at Scopus
  39. S. J. Kish, K. Shannak, and O. Hornykiewicz, “Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications,” New England Journal of Medicine, vol. 318, no. 14, pp. 876–880, 1988. View at Google Scholar · View at Scopus
  40. Y. Ichitani, H. Okamura, D. Nakahara, I. Nagatsu, and Y. Ibata, “Biochemical and immunocytochemical changes induced by intrastriatal 6-hydroxydopamine injection in the rat nigrostriatal dopamine neuron system: evidence for cell death in the substantia nigra,” Experimental Neurology, vol. 130, no. 2, pp. 269–278, 1994. View at Publisher · View at Google Scholar · View at Scopus
  41. S. Przedborski, M. Levivier, H. Jiang et al., “Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine,” Neuroscience, vol. 67, no. 3, pp. 631–647, 1995. View at Publisher · View at Google Scholar · View at Scopus
  42. D. C. German and K. F. Manaye, “Midbrain dopaminergic neurons (nuclei A8, A9, and A10): three-dimensional reconstruction in the rat,” Journal of Comparative Neurology, vol. 331, no. 3, pp. 297–309, 1993. View at Google Scholar · View at Scopus
  43. E. Riquelme, Expresion en substantia nigra mesencefalica de trkB, receptor de BDNF, y su regulacion por receptores de glutamato tipo NMDA, frente a un daño progresivo de la via dopaminergica nigroestriatal. Posibles implicancias en relacion a la fase premotora y/o presintomatica de la enfermedad de Parkinson, Ph.D. thesis, Facultad de Ciencias Biologicas, Pontificia Universidad Catolica de Chile, Santiago, Chile, 2011.
  44. L. Frank, “BDNF down-regulates neurotrophin responsiveness, TrkB protein and TrkB mRNA levels in cultured rat hippocampal neurons,” European Journal of Neuroscience, vol. 8, no. 6, pp. 1220–1230, 1996. View at Publisher · View at Google Scholar · View at Scopus
  45. M. T. Sommerfeld, R. Schweigreiter, Y. A. Barde, and E. Hoppe, “Down-regulation of the neurotrophin receptor TrkB following ligand binding. Evidence for an involvement of the proteasome and differential regulation of TrkA and TrkB,” Journal of Biological Chemistry, vol. 275, no. 12, pp. 8982–8990, 2000. View at Publisher · View at Google Scholar · View at Scopus
  46. F. Gardoni, B. Picconi, V. Ghiglieri et al., “A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia,” Journal of Neuroscience, vol. 26, no. 11, pp. 2914–2922, 2006. View at Publisher · View at Google Scholar · View at Scopus
  47. F. Blandini, G. Nappi, C. Tassorelli, and E. Martignoni, “Functional changes of the basal ganglia circuitry in Parkinson's disease,” Progress in Neurobiology, vol. 62, no. 1, pp. 63–88, 2000. View at Publisher · View at Google Scholar · View at Scopus
  48. T. J. Kingsbury, P. D. Murray, L. L. Bambrick, and B. K. Krueger, “Ca2+-dependent regulation of TrkB expression in neurons,” Journal of Biological Chemistry, vol. 278, no. 42, pp. 40744–40748, 2003. View at Publisher · View at Google Scholar · View at Scopus
  49. K. R. Gogas, “Glutamate-based therapeutic approaches: NR2B receptor antagonists,” Current Opinion in Pharmacology, vol. 6, no. 1, pp. 68–74, 2006. View at Publisher · View at Google Scholar · View at Scopus
  50. G. E. Hardingham and H. Bading, “Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders,” Nature Reviews Neuroscience, vol. 11, no. 10, pp. 682–696, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. J. M. Loftis and A. Janowsky, “The N-methyl-D-aspartate receptor subunit NR2B: localization, functional properties, regulation, and clinical implications,” Pharmacology and Therapeutics, vol. 97, no. 1, pp. 55–85, 2003. View at Publisher · View at Google Scholar · View at Scopus
  52. C. Leon-Perez, “Efecto de K252A, antagonista del receptor del factor neurotrofico derivado de cerebro (BDNF), sobre la liberacion de glutamato, aspartato, acido gama aminobutırico y dopamina, en cuerpo estriado y substantia nigra de rata: estudios in vivo mediante la tecnica de microdıalisis,” Memoria de Investigacion para optar al tıtulo de Bioquımico, Facultad de Ciencias Biologicas, Pontificia Universidad Catolica de Chile, Santiago, Chile, 2006. View at Google Scholar
  53. S. W. Jang, X. Liu, M. Yepes et al., “A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 6, pp. 2687–2692, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. S. A. Mandel, Y. Sagi, and T. Amit, “Rasagiline promotes regeneration of substantia nigra dopaminergic neurons in post-MPTP-induced parkinsonism via activation of tyrosine kinase receptor signaling pathway,” Neurochemical Research, vol. 32, no. 10, pp. 1694–1699, 2007. View at Publisher · View at Google Scholar · View at Scopus